O 
4.00
+3.63%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Oramed Pharmaceuticals
From its filings with the US Securities and Exchange Commission
Oramed Pharmaceuticals is based in New York, New York and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker ORMP. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported revenue of $2.0m and net income of $64.0m. At that date it held total assets of $230.9m and shareholders' equity of $199.7m.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 1 Apr 2002
- Employees
- 12
- Website
- oramed.com ↗
- Head office
- 1185 AVENUE OF THE AMERICAS, 3RD FLOOR, NEW YORK, NY, 10036
- Incorporated in
- DE
- Classification
- Pharmaceutical Preparations
- Filer status
- Non-accelerated filer<br>Smaller reporting company
Leadership
Pay as last reported
- Mr. Nadav KidronChairman of the Board, President, Chief Executive Officer, since 2006$2.1m
- Mr. Avraham GabayChief Financial Officer, Treasurer, Secretary$1.0m
- Mr. Joshua HexterChief Operating and Business Officer$1.0m
- Dr. Miriam KidronChief Scientific Officer, Director, since 2006$1.5m
- Dr. Daniel AghionIndependent Director$134,637
- Dr. Arie MayerIndependent Director$135,950
- Mr. Yehuda ReznickIndependent Director$100,628
- Mr. Leonard SankIndependent Director, since 2007$135,104
- Mr. Benjamin ShapiroIndependent Director$113,817
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 26
- Environment
- 30
- Social
- 17
- Governance
- 31
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Oramed Pharmaceuticals Inc possesses a unique and innovative oral drug delivery technology, allowing for the oral administration of proteins and other therapeutic molecules. This technology provides a competitive advantage by addressing the limitations of traditional injectable drug delivery methods.
- Oramed has developed a robust intellectual property portfolio with a strong focus on its proprietary oral drug delivery technology. This portfolio includes patents and trademarks that provide protection and exclusivity for their innovative solutions, enhancing their market position and future growth prospects.
- Oramed has established strategic collaborations and partnerships with various pharmaceutical companies and research institutions. These collaborations create opportunities for knowledge sharing, research funding, and potential licensing or commercialization agreements, supporting Oramed's growth and expanding its reach in the industry.
Weaknesses
- Oramed currently has a limited product pipeline, with most of their focus on the development of an oral insulin product. This concentration poses a potential risk if the development or regulatory approval of their flagship product faces challenges or setbacks. Diversifying their product portfolio could mitigate this weakness.
- Oramed's success heavily relies on obtaining regulatory approvals for its oral drug delivery technology and products. Delays or rejections in the approval process can significantly impact their business and hinder their ability to generate revenue. Close monitoring and effective management of regulatory matters are crucial to minimize this weakness.
Opportunities
- The global market demand for oral drug delivery systems is on the rise, driven by patient preference for non-invasive treatments and improved medication adherence. Oramed's oral drug delivery technology places them in a favorable position to capitalize on this opportunity and cater to the evolving needs of patients and healthcare providers.
- Oramed can explore expansion opportunities into new therapeutic areas beyond diabetes. By leveraging their proprietary technology and scientific expertise, they can potentially develop oral delivery solutions for various other therapeutic molecules. This expansion could broaden their product portfolio and diversify their revenue streams.
Threats
- Oramed operates in a highly competitive pharmaceutical industry where numerous companies are engaged in drug development and innovative delivery technologies. The presence of well-established competitors with significant resources and expertise poses a threat to Oramed's market share and growth potential. Continuous innovation and differentiation are essential to withstand this competition.
- Complying with strict regulatory requirements and maintaining compliance with evolving healthcare regulations can be challenging and time-consuming for Oramed Pharmaceuticals Inc. Changes in regulatory policies, safety concerns, or legal issues could disrupt their operations, impede product development, or result in costly litigation. Staying abreast of regulatory changes and implementing appropriate risk management strategies is crucial.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.